# COVIDIG (COVID-19 Hyper-ImmunoGlobulin)

> **NCT04555148** · PHASE2 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 63 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** GC5131
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04555148
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-19
- **Primary completion:** 2021-01-22
- **Final completion:** 2021-04-23
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2021-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04555148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04555148, "COVIDIG (COVID-19 Hyper-ImmunoGlobulin)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04555148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*